We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-1.57%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.47B
AUM Growth
-$458M
Cap. Flow
+$15.5M
Cap. Flow %
0.35%
Top 10 Hldgs %
43.81%
Holding
163
New
19
Increased
16
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$65.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$64M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$58.4M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$56.3M
5
OMGA
Omega Therapeutics, Inc. Common Stock
OMGA
+$43.6M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$65.4M
2
XLRN
Acceleron Pharma
XLRN
+$52.3M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.8M
4
SEER icon
Seer Inc
SEER
+$28.8M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$24.3M

Sector Composition

Rank Sector Weight
1 Healthcare 82%
2 Consumer Discretionary 6.51%
3 Financials 0.67%
4 Consumer Staples 0.51%
5 Materials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LXRX icon
1
Lexicon Pharmaceuticals
LXRX
$1.03B
$342M 7.66%
71,178,364
– –
WW
2
DELISTED
WW International
WW
$270M 6.05%
14,818,300
– –
ONC
3
BeOne Medicines Ltd
ONC
$33.9B
$236M 5.28%
650,000
-200,000
-24% -$65.4M
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$212M 4.75%
1,200,000
+350,000
+41% +$56.3M
ARGX icon
5
argenx
ARGX
$55.1B
$174M 3.9%
577,308
+77,308
+15% +$24.5M
XLRN
6
DELISTED
Acceleron Pharma
XLRN
$172M 3.85%
1,000,000
-400,000
-29% -$52.3M
SEER icon
7
Seer Inc
SEER
$115M
$164M 3.67%
4,750,000
-838,366
-15% -$28.8M
C icon
8
CALL
Citigroup
C
$216B
$140M 3.14%
2,000,000
-750,000
-27% -$52.4M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.5B
$132M 2.96%
700,000
-50,000
-7% -$9.38M
FCX icon
10
CALL
Freeport-McMoran
FCX
$85.2B
$114M 2.55%
3,500,000
+2,750,000
+367% +$96.8M
MORF
11
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$89.8M 2.01%
1,585,049
-234,137
-13% -$14.2M
IGMS
12
DELISTED
IGM Biosciences
IGMS
$88.8M 1.99%
1,350,000
+250,000
+23% +$19.1M
FATE icon
13
Fate Therapeutics
FATE
$267M
$85.9M 1.92%
1,450,000
+100,000
+7% +$7.84M
RUBY
14
DELISTED
Rubius Therapeutics, Inc
RUBY
$74.3M 1.66%
4,155,625
-478,166
-10% -$10.4M
GBIO
15
DELISTED
Generation Bio
GBIO
$70.6M 1.58%
281,419
– –
ERAS icon
16
Erasca
ERAS
$6.14B
$67.3M 1.51%
+3,172,221
New +$65.4M
SRRK icon
17
Scholar Rock
SRRK
$5.88B
$64.4M 1.44%
1,950,000
-50,000
-3% -$1.75M
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
$64M 1.43%
6,696,955
+2,946,955
+79% +$30.1M
SGEN
19
DELISTED
Seagen Inc. Common Stock
SGEN
$63.7M 1.42%
+375,000
New +$58.4M
NBP
20
NovaBridge Biosciences American Depositary Shares
NBP
$195M
$59.8M 1.34%
825,000
+75,000
+10% +$5.42M
BMY icon
21
CALL
Bristol-Myers Squibb
BMY
$130B
$59.2M 1.32%
1,000,000
– –
KLRS
22
Kalaris Therapeutics
KLRS
$80.4M
$58.2M 1.3%
101,016
– –
CERE
23
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$53.1M 1.19%
1,800,000
-200,000
-10% -$5.61M
CYTK icon
24
Cytokinetics
CYTK
$10.8B
$46.5M 1.04%
1,300,000
+800,000
+160% +$23.6M
SAGE
25
DELISTED
Sage Therapeutics
SAGE
$44.3M 0.99%
1,000,000
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2021 Portfolio in Review

As of Q3 2021, Artal Group held 163 positions worth $4.47B, down 9.3% from $4.93B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q3 2021 filing shows 19 new, 16 increased, 16 reduced and 17 closed positions. Its largest new stake was Erasca: 3,172,221 shares worth $67.3M. The largest sale was BeOne Medicines Ltd, an estimated $65.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 74% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q3 2021 buy was Erasca: 3,172,221 shares worth $67.3M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q3 2021, an estimated $56.3M increase.
  • Artal Group's biggest Q3 2021 reduction was BeOne Medicines Ltd, cutting an estimated $65.4M.
  • Artal Group fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2021, selling an estimated $38.8M.
  • Artal Group's ten largest holdings make up 44% of its $4.47B portfolio in Q3 2021.
  • Artal Group opened 19 new positions and closed 17 in Q3 2021.
  • Artal Group's portfolio value fell 9.3% quarter-over-quarter to $4.47B.

Based on Artal Group's 13F filing for Q3 2021, filed 12 Nov 2021.